Tagged with Regulation,

Pharma Europe’s longest-standing Minister of Health, Edith Schippers, provides insight into the local healthcare system and continued efforts to improve quality of life for Dutch citizens, as well as revealing the main policy priorities of the Ministry for the Dutch presidency of the European Union in the first semester of 2016.…

Pharma The Managing Director of MSD Egypt highlights MSD’s unique incentives to further collaborate with the Egyptian medical community and explains how market peculiarities shape product launches in developing countries like Egypt. As newly appointed Managing Director for MSD Egypt, could you please outline your objectives and ambitions in the Egyptian…

Pharma Deputy Minister of Health for Pharmaceutical Affairs Tarek Salman discusses how pharmaceutical regulation in Egypt is taking a leap forward, with the introduction of new legislation with parallel registration process that will bring approval timelines under 21 months, and the imminent establishment of the Egyptian Drug Authority, which will merge…

Pharma The Italian Medicines Agency, AIFA, sits at a crossroads. Its Director-General Prof. Luca Pani discusses the apparent contradiction in the agency’s mission at a time of constricting budgets and expensive medicines, how the agency’s role is evolving in response and in which ways the agency can collaborate with the industry.…

pharma Harnessing the power of big data and the Internet, myTomorrows is working to help patients in need to access treatments that would otherwise not be available outside of a clinical trial. CEO Ronald Brus discusses the workings of this unique and disruptive company. As an introduction, given your wealth of experience in…

pharma The managing director of Southern Medical, Malan de Villiers illustrates the sheer diversity of the company’s current activities and portfolio within South Africa as a leading implant devices company, while depicting his vision on the South African medical device market. He also reveals the competitive and regulatory challenges in the…

pharma Escalate Sciences is a Puerto Rican specialized science-based consulting firm focused on R&D, tech transfer, process design & improvement, analytical development and characterization. The company also serves different aspects of the life-sciences industry including project management, validation, qualification, statistical analysis, facility start-up, regulatory & compliance, reformulation and testing services. Its…

pharma Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking the sector’s potential in Italy. Leonardo, to start off, what are some of the major milestones which the industry, and…

pharma The founder and managing director of LT Clinical Research, one of the first wholly black-owned South African CRO, reveals how South Africa is a very conducive environment for CROs, with a diverse patient population, a well-established regulatory framework and a currency that compares well to other African currencies; why the…

pharma The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs to look at how to evaluate real needs, why the patient has to become more involved in the decisionmaking process,…

Pharma The Vice-Chairman of the Public Health Enhancement Fund talks about how the shortage of medical doctors and the fight against TB, HIV and AIDS in South Africa led the health Minister and the private health sector to create a public health enhancement fund and how the private sector is pulling resources…

pharma IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his perspective about the Dutch healthcare and life sciences market, the challenges it poses and what companies can expect for the…